Ardelyx, Inc. (ARDX) is a biopharmaceutical company focused on innovative therapies for gastrointestinal and kidney diseases. This report evaluates its Shariah compliance based on financial ratios, business activities, index inclusion, and multi-perspective analysis. While financial screens indicate compliance with key thresholds, the absence of inclusion in major Shariah indices results in an overall non-compliant status. Purification is required for minor interest income, and ESG factors align well with Islamic principles. Investors should monitor for potential index eligibility as the company grows.